According to filings with the U.S. Securities and Exchange Commission, UroGen Pharma is raising $120,000,000.00 in new funding. Sources indicate that as part of senior management Chief Financial Officer, Don Kim played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About UroGen Pharma
UroGen Pharma is a biopharmaceutical company that builds novel solutions to revolutionize the way specialty cancers and urologic diseases are treated because patients deserve better options. Our vision is grounded in our RTGel drug delivery technology platform, our promising pipeline, and a collaborative drive for bold results. Our existing technology: the RTGel drug delivery platform has the potential to be applied to a variety of unmet medical needs. RTGel reverse-thermal hydrogel is liquid at lower temperatures and converts to gel form at body temperature, offering the opportunity to make local therapy a more effective treatment. Our promising pipeline: Ranging from pre-clinical to Phase III, we currently have multiple candidates in our pipeline, which are furthering the study of potential treatment advances in urology, uro-oncology, and immunology. Our collaborative drive: We are part of a broad ecosystem of partners who are seeking to improve patient care; these connections are vital to our commitment to offer new pathways and advance solutions. We currently have an exclusive worldwide license agreement with Allergan to evaluate the RTGel platform, an early-stage feasibility agreement with Janssen Pharmaceuticals, and are continually evaluating new opportunities.

To learn more about UroGen Pharma, visit http://urogen.com/

Contact:
Don Kim, Chief Financial Officer
646-768-9780

SOURCE: http://www.intelligence360.io
Copyright (c) 2023 SI360 Inc. All rights reserved.